.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,972,967

« Back to Dashboard
Patent 5,972,967 protects AGGRASTAT and is included in two NDAs.

This patent has forty-four patent family members in thirty-five countries.

Summary for Patent: 5,972,967

Title: Compositions for inhibiting platelet aggregation
Abstract:The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid; b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; and c) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.
Inventor(s): Gelotte; Karl M. (North Wales, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/965,922
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 1st percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Medicure
AGGRASTAT
tirofiban hydrochloride
INJECTABLE;INJECTION020912-001May 14, 1998DISCNNo5,972,967► subscribe
Medicure
AGGRASTAT
tirofiban hydrochloride
SOLUTION;INJECTION020912-002Aug 31, 2016RXYes5,972,967► subscribeY
Medicure
AGGRASTAT
tirofiban hydrochloride
INJECTABLE;INJECTION020913-002May 17, 2002RXNo5,972,967► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,972,967

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,965,581 Compositions for inhibiting platelet aggregation► subscribe
5,733,919 Compositions for inhibiting platelet aggregation► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,972,967

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina004223► subscribe
Austria213648► subscribe
Australia712755► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc